Novartis CEO sees China M&A hampered by data, regulatory standards

Novartis Chief Executive Vas Narasimhan said takeover targets in China for global pharmaceuticals companies are scarce due to little drug discovery by local firms, worries over data quality and regulatory standards in the most-populous country.

…read more

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News